/index.php?option=com_iwpfile&file=/dir_01/he2002_2586.pdf

/index.php?option=com_iwpfile&file=/dir_01/he2002_2585.pdf

For Immediate Release:

Oct. 8, 2002

Contact: Angela Bradbery

(202) 588-7741

Booth Gunter

(202) 588-7703

33 Deaths Among Military Prompted Ephedra Ban; FDA Should Follow Suit

Memo Shows FDA Official Acknowledges Link Between Ephedra and Heart Problems


/index.php?option=com_iwpfile&file=/dir_01/he2002_2583.pdf

le

FOR IMMEDIATE RELEASE

November 6, 2002

Contact: Richard Sellers

703/524-0810; rsellers@afia.org

AFIA ASSEMBLES INDUSTRY TEAM TO RESPOND TO

FDA BSE FEED RULE PROPOSAL


AM

The new label warns that LARIAM may cause psychiatric symptoms in a number of patients. Roche letter to pharmacists Roche letter to doctors


Infections

Press Release

Update: Listeriosis Outbreak Investigation

Update October 3, 2002 Contact: CDC, Media Relations (404) 639" 3286


Infections

October 4, 2002 Contact: CDC Media Relations 404-639-3286

Press Release

E.coli O157:H7 Outbreak Investigations

O157:H7 infections.


FOR IMMEDIATE RELEASE:

Monday, October 7 , 2002

CONTACT: Ken Johnson or Arturo Silva

202.225.5735

Greenwood Announces Hearing

On The ImClone Erbitux Story

WASHINGTON (October 7) -- House Energy and Commerce Oversight and Investigations Subcommittee Chairman James Greenwood (R-PA) has scheduled a hearing for Thursday (October 10 at 10:00 a.m. in room 2123 of the Rayburn House Office Building) entitled, "An Inquiry into the ImClone Cancer-Drug Story."


In a Sept. 25 letter to the Senate Finance Committee leader, CMS Administrator Tom Scully is requesting action on the administration's top legislative priorities: contractor reform, competitive bidding for durable medical equipment, and Medicare benefit improvements. Scully advises, however, that many provisions in the Senate's original regulatory reform bill, which was introduced last year, could be counterproductive as CMS has already implemented such changes.


Pages

Log in to access this content.

Not a subscriber? Sign up for 30 days free access to exclusive, detailed reporting on drug pricing reforms, Medicaid policy, FDA news and much more.